New Trial in the Making???

[Guest guest]

Conclusions: AEG35156 reduces XIAP levels and sensitizes tumors to chemotherapy.

It is presently under clinical assessment in multiple phase I trials in cancer

patients as a single agent and in combination with docetaxel in solid tumors or

cytarabine/idarubicin in leukemia. XIAP is recognized to be the most potent

member of the IAP family with respect to caspase inhibition, with Kis in the

high picomolar range, and its overexpression provides the greatest protection

for cells both in vitro and in vivo from apoptotic events and conditions. There

is growing evidence that activity of XIAP, and perhaps other IAPs, extends

beyond the inhibition of caspases and that multiple cellular events may

contribute to the overall antiapoptotic activity of XIAP.

http://clincancerres.aacrjournals.org/cgi/content/abstract/12/17/5231

FYI,

Lottie